OR WAIT null SECS
Cyxone has appointed a European CDMO to scale-up and produce the active ingredient of its T20K drug candidate.
Developer of disease modifying therapies, Cyxone, has appointed a European contract development and manufacturing organization (CDMO) to scale-up and produce the active ingredient of its T20K drug candidate.
According to a Jan. 18, 2022 press release, the agreement will initially cover method development and then, at a later stage, will include the supply of material for use in non-clinical and clinical development activities. Additionally, production of the active ingredient will be performed in accordance with good manufacturing practice (GMP), exploring a novel manufacturing method.
T20K is a peptide that has been developed for the treatment of multiple sclerosis. The drug has demonstrated the potential capability of preventing disease progression in a model system at the preclinical stage.
“We are pleased to have established a collaboration with one of Europe’s leading manufacturers of therapeutic peptides,” said Tara Heitner, CEO, Cyxone, in the press release. “T20K GMP manufacturing is an important step before non-clinical safety studies and future clinical studies. A feasibility study will be the first step of this collaboration permitting further optimization of the scale up process. The agreement represents our commitment to the T20K program and indicates that we are on schedule with our non-clinical plans.”